Drug Type Antibody drug conjugate (ADC) |
Synonyms MTX 1000, MTX1000 |
Target |
Action modulators |
Mechanism HER2 modulators(Receptor tyrosine-protein kinase erbB-2 modulators), HER3 modulators(Receptor tyrosine-protein kinase erbB-3 modulators), Trop-2 modulators(Tumor-associated calcium signal transducer 2 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Colorectal Cancer | Preclinical | China | 03 Apr 2023 | |
| Lung Cancer | Preclinical | China | 03 Apr 2023 |






